enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference [Yahoo! Finance]
enGene Holdings Inc. (ENGN)
Company Research
Source: Yahoo! Finance
The LEGEND pivotal cohort completed enrollment at 125 patients, and post-amendment data from 62 of 94 patients showed roughly a 62% six-month complete response (CR) with mostly Grade 1–2 adverse events and low discontinuation rates. enGene's non-viral EDV platform is positioned for community use (re-dosable, simple storage/handling), the company is advancing manufacturing toward FDA validation batches with a CDRP designation, and it reports cash runway into the second half of 2028. Interested in enGene Holdings Inc.? Here are five stocks we like better. enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper outlined the company's near-term regulatory and clinical plans for its lead program, detalimogene voraplasmid, during a presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference. Cooper said the company expects to provide an update from its pivotal study in the second half of 2026, submit a biologics license application (BLA) by year-end 2026, and target
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene to Participate in Upcoming Investor ConferencesBusiness Wire
- Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) [Yahoo! Finance]Yahoo! Finance
- enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Business Wire
- Both private equity firms who control a good portion of enGene Holdings Inc. (NASDAQ:ENGN) along with institutions must be dismayed after last week's 16% decrease [Yahoo! Finance]Yahoo! Finance
- enGene (NASDAQ:ENGN) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
ENGN
Sec Filings
- 3/3/26 - Form EFFECT
- 2/19/26 - Form S-3
- 2/19/26 - Form 10-K/A
- ENGN's page on the SEC website